StockData
Agenus Inc logo

Agenus Inc (AGEN) stock

AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$6.21−0.08 (-1.27%)

Close on Nov 17, 2026Market cap $279.58MP/E –Yield –

Agenus Inc grew revenue 30.5% to $132.69M over the twelve months to Jun 30, 2026. Free cash flow was -$98.50M. At the latest close the market valued the company at $279.58M.

Revenue
$132.69M
+30.5% vs. a year earlier
Operating income
$36.20M
TTM Q2 2026
Free cash flow
-$98.50M
TTM Q2 2026
EPS, diluted
$0.00
FY2025

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$279.58M
P/E ratio
–
Price to sales
2.11
Price to book
–
Dividend yield
–
Free cash flow yield
-35.23%

Fundamentals

Revenue
$132.69M
EPS, diluted
$0.00
Free cash flow
-$98.50M
Book value per share
-$4.82
Diluted shares
41M

Trading

Next earnings
Mar 15, 2027 (estimated, before the open)
Previous close
$6.29
Open
$6.19
Day's range
$5.96 – $6.45
Volume
859,413
Average volume (20 days)
685,142
Index membership
Russell 2000 (since Jun 2026)
52-week range
$2.71 – $10.31
RSI (14 days)
41.5
Volatility (1 year)
120.6%
Relative volume
0.18×

On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2015, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodAGENS&P 500DifferenceAGEN per yearS&P 500 per year
1 month+2.8%-3.1%+5.9 pts
3 months-13.1%-4.0%−9.1 pts
Year to date+97.8%+9.4%+88.4 pts
1 year+43.8%+12.4%+31.4 pts
3 years-55.0%+70.2%−125.2 pts-23.4%+19.4%
5 years-91.0%+69.0%−160.0 pts-38.3%+11.1%
10 years-93.8%+295.7%−389.5 pts-24.3%+14.7%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$132.69M+30.5% YoY

Gross profit

$132.05M+30.7% YoY

Operating income

$36.20M

Net income

–

EPS, diluted

–

Free cash flow

-$98.50M
Reported periodTrailing twelve months

Press releases

Releases Agenus filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Agenus

Biological Products, (No Diagnostic Substances)

Agenus Inc. operates as a commercial-stage and clinical biopharmaceutical company focused on clinical products, pre-commercial products, and clinical research services. The company provides specialized research and development manufacturing services, licenses proprietary intellectual property, and manages collaborative commercial agreements. Its primary operational activities encompass clinical product distribution, contract research, collaborative agreements, and named patient programs. Agenus engages with commercial customers and healthcare partners, including Incyte Corporation, Bristol Myers Squibb, Gilead Sciences, Betta Pharmaceuticals, and GlaxoSmithKline.

Company profile, executives and history

Agenus stock: common questions

What is Agenus's stock price?

AGEN closed at $6.21 on Nov 17, 2026, down 1.27% on the day. Over the past 52 weeks it traded between $2.71 and $10.31.

What is Agenus's market cap?

Agenus was worth $279.58M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is AGEN's P/E ratio?

Agenus lost money over fiscal 2025 (diluted EPS $0.00), so it has no meaningful P/E ratio.

How much revenue does Agenus make?

Agenus reported revenue of $132.69M for the twelve months to Jun 30, 2026, up 30.5% from a year earlier.

Does Agenus pay a dividend?

No. Agenus has not paid a cash dividend over the last twelve months.

When does Agenus report earnings next?

Agenus is expected to report Q4 FY2026 results on Mar 15, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has AGEN stock performed over the past year?

Including dividends, AGEN returned +43.8% over the past year, against +12.4% for the S&P 500.

How many AGEN shares are sold short?

8M shares were sold short at the latest FINRA report, 18.06% of the float, or 10.7 days of average trading volume.

Who are Agenus's competitors?

Companies most similar to Agenus by business, industry and size include BEAM, RGNX, DNA, AUTL, GLUE.

See a number that looks wrong?